Mark William Ahrens-Townsend

Mark William Ahrens-Townsend discloses dealings in Kane Biotech Inc. to SEDI. Over a trading history stretching from 16 February 2016 to 27 March 2018, the count stands at 7 filings.

Purchases make up the whole of the open-market record (3 purchases, €5,332). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 1 option exercise. 2018 to date brings 2 purchases and no sales.

A typical purchase (the median) is worth €1,188. None of the 3 purchases we analysed coincided with buying by another insider of the same company within 30 days.

The latest filing, published on 27 March 2018, reports an open-market purchase of €1,188 in Kane Biotech Inc. Most trades are made public on the day they happen. That lag is the time during which only the insider knows about the trade. These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.